SCHEMBL6859666

SCHEMBL6859666

C[C@H](NC(=O)C=Cc1cccc(F)c1)c1cccc(-c2ccc(F)nc2)c1

nearest known ligand 0.74

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.49
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
LMNA P02545 2/20 0.45
KMT2A Q03164 2/20 0.45
KCNQ2 O43526 2/20 0.43
CYP3A4 P08684 2/20 0.43
KCNQ3 O43525 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP19A1 P11511 1/20 0.43
CYP2C9 P11712 1/20 0.43
ROCK2 O75116 1/20 0.43
KDM4E B2RXH2 1/20 0.41
LIPG Q9Y5X9 1/20 0.41
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6859663 1.00 TDP1 (0.49) TDP1NPC1RAB9ASMN1; SMN2LMNA
SCHEMBL6859667 1.00 TDP1 (0.49) TDP1NPC1RAB9ASMN1; SMN2LMNA
SCHEMBL6859655 0.94 TDP1 (0.46) TDP1NPC1RAB9ASMN1; SMN2LMNA
SCHEMBL6859658 0.94 TDP1 (0.46) TDP1NPC1RAB9ASMN1; SMN2LMNA
SCHEMBL6859653 0.94 TDP1 (0.46) TDP1NPC1RAB9ASMN1; SMN2LMNA
SCHEMBL6627710 0.93 TDP1 (0.59) TDP1LMNAKMT2AKCNQ2CYP3A4
SCHEMBL6627707 0.93 TDP1 (0.59) TDP1LMNAKMT2AKCNQ2CYP3A4
SCHEMBL6627711 0.93 TDP1 (0.59) TDP1LMNAKMT2AKCNQ2CYP3A4
SCHEMBL6625908 0.92 MEN1 (0.51) TDP1SMN1; SMN2LMNAKMT2AKCNQ2
SCHEMBL30794965 0.92 MEN1 (0.51) TDP1SMN1; SMN2LMNAKMT2AKCNQ2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831080-B2 E.g., 3-(2-fluorophenyl)-N-(1-(3-morpholin-4-yl)phenyl)-propyl)acrylamide; disorders responsive to opening of KCNQ potassium channels; analgesics; migraine, bipolar disorders, anticonvulsants, antiepileptic, anxiolytic agents BRISTOL-MYERS SQUIBB COMPANY 2004-12-14 US disclosed